AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC (LSE:AZN) has secured US approval for a new breast cancer treatment, Truqap (capivasertib), to be used in combination with Faslodex (fulvestrant). It brings hope for a specific group of sufferers: adult women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic forms of the disease, who have specific genetic biomarkers (PIK3CA, AKT1, or PTEN).

AstraZeneca gets US sign-off for breast cancer combination

Chubb

Eaton

Novo Nordisk

NXP Semiconductors

Shell PLC

Investors in Eurozone stocks have been taken for a roller-coaster ride thus far this year. These stocks performed strongly during the first several months of 2023 as the pace of economic activity and company profits beat market expectations.

When Will It Again Be Safe To Invest In Eurozone Stocks?

The U.S. Food and Drug Administration on Thursday approved AstraZeneca's drug capivasertib in combination with an older drug, providing another treatment option for patients with the most common type of breast cancer.

US FDA approves AstraZeneca's breast cancer drug combination

Sanofi

The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.

CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

AllianceBernstein Hld

Arbor Realty Trust

Ares Capital

Alexandria Real Estate Equities

BHP Billiton

British American Tobacco

CVS Health

Discover

Fifth Third Bancorp

Hasbro

Navient

NexPoint Residential Trust

Pfizer

Philip Morris

Vici Properties

March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five sets of stocks sorted as: “Inflation Busters.” Those five articles revealed 48 equities, with 43 paying dividends.

13 Buyable Inflation-Busting November Dividend Stocks

AstraZeneca said a trial of its Imfinzi drug as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy (CRT) failed to make a statistically significant difference to patients. Primary endpoint for the trial [PACIFIC -2] was progression-free survival (PFS) versus CRT alone for the treatment of patients with unresectable, stage III non-small cell lung cancer (NSCLC).

AstraZeneca to learn from latest Imfinzi trial after endpoint not met

Drugmaker AstraZeneca said on Tuesday its cancer drug Imfinzi administered with chemoradiotherapy failed to meet its main goal in a late-stage trial to treat unresectable, Stage 3 non-small cell lung cancer.

AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal in late stage trial

Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock

BioNTech SE

Boston Scientific

Senti Biosciences Inc

Eccogene out-licenses global rights for its GLP-1 agonist to AstraZeneca in a $2 billion deal. Biotheus sells ex-China rights for a bispecific antibody candidate to BioNTech for $55 million upfront. WuXi XDC conducts a $500 million Hong Kong IPO to expand its manufacturing capacity for ADCs and bioconjugates.

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.

AstraZeneca prioritizes US for RSV drug amid surge in cases

Abbott Labs

Anheuser-Busch InBev

Crown Hlds

Chipotle

DoorDash

Darden Restaurants

Fresenius Medical Care

Hershey

Keurig Dr Pepper Inc

Eli Lilly

Mondelez

PepsiCo

Teleflex

That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.

Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

Costco

Salesforce

Chevron

Li Auto Inc.

Lockheed Martin

Rio Tinto plc Sponsored

Millionaires, by investing in equities, are not made overnight. It takes years of grinding in the form of research that a high level of patience should back.

The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire

AstraZeneca PLC (NASDAQ:AZN ) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET Corporate Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer, Alexion Conference Call Participants Steve Scala - Cowen Gonzalo Artiach - ABG Andrew Baum - Citi Sachin Jain - Bank of America Tim Anderson - Bernstein Emily Field - Barclays James Gordon - JPMorgan Mattias Häggblom - Handelsbanken Mark Purcell - Morgan Stanley Eric Le Berrigaud - Stifel Richard Parkes - BNP Christopher Uhde - SEB Simon Baker - Redburn Luisa Hector - Berenberg Emmanuel Papadakis - Deutsche Bank Peter Welford - Jefferies Operator Good morning to those joining from the U.S. Good afternoon to those in the U.K. and Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen to AstraZeneca's Nine Months and Q3 Results 2023 Conference Call and Webinar for Investors and Analysts.

AstraZeneca PLC (AZN) Q3 2023 Earnings Call Transcript

AstraZeneca (AZN) announced a deal for an experimental weight-loss pill and raised its guidance on higher demand for its cancer treatments.

AstraZeneca Strikes a Deal for an Experimental Weight-Loss Drug and Boosts Its Guidance

A UK father and a widower have filed lawsuits against AstraZeneca PLC (LSE:AZN), claiming that the Oxford-AstraZeneca Covid-19 vaccine was defective and caused blood clots and brain injuries to their loved ones, according to reports.   Two court cases were filed by relatives of patients of the vaccine in the High Court who developed a rare and potentially deadly neurological condition, one of whom died, which imply the vaccine was “defective”.

AstraZeneca faces lawsuits in High Court over ‘defective' Covid-19 vaccine

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

AstraZeneca has struck a licensing deal worth up to $2 billion for a weight-loss drug. Stockholders are welcoming the move as its shares have lagged behind peers Eli Lilly and Novo Nordisk.

AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.

Shares of AZN stock popped Thursday after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.

AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs

The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.

AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows

AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide obesity drug will make up for concerns over its Covid-19 vaccine and bolster sales growth driven by its cancer drug.  The pharmaceuticals group reported a 5% increase in turnover for the year to date to US$33.8 billion, with oncology sales rising by a fifth, but according to analysts took a US$2.9 million knock from a slump in Covid-19 medicine sales.

AstraZeneca: "Take some reassurance” from obesity drug bet

UK drugmaker signs agreement with China's Eccogene to work on an obesity and type 2 diabetes pill

AstraZeneca makes bigger push into weight-loss market with new drug deal

Anglo-Swedish drugmaker AstraZeneca on Thursday upped its earnings forecasts for the year as surging sales of cancer medicines offset plummeting sales of COVID vaccines.

AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines

News for AstraZeneca Stock (AZN)